 Inhibitor of stem cell proliferation and uses thereof |
| The present invention relates to polypeptides which are inhibitors of stem cell proliferation ("INPR... |
|
| Inhibitor of stem cell proliferation and uses thereof |
| The present invention relates to an inhibitor of stem cell proliferation (INPROL) characterized by ... |
|
| Method of inhibiting angiogenesis using secreted proteins |
| Isolated Proteins Nucleotide and amino acid sequences, as presently determined, are reported below ... |
|
| Balanced extraction system |
| The present invention is a device wherein matter to be extracted which contains various available ... |
|
| Compounds for the treatment of hepatoma |
| What is claimed is: 1. The method of treatment of a living subject affected by hepatoma which ... |
|
| 5ht2 agonists for controlling IOP and treating glaucoma |
| 1. A method for lowering or controlling intraocular pressure or treating glaucoma which comprises ... |
|
| Insect resistant tomato and potato plants |
| We claim: 1. A chimeric gene capable of expressing in a plant cell comprising in sequence: (a) a ... |
|
| Insect resistant plants |
| In accordance with one aspect of the present invention, there has been provided a method for ... |
|
| Hybrid toxin |
| What is claimed is: 1. An insecticidal Bacillus thuringiensis hybrid toxin fragment, comprising: a) ... |
|
| Antigenic proteins of Borrelia burgdorferi |
| It is an object of the present invention to provide a means for detecting mammals previously or ... |
|
|
Methods of treating inflammatory bowel disease using cholera toxin B subunit
| Details |
Inventors: Stober, Warren; Fuss, Ivan J.; Kelsall, Brian L.; Boirivant, Monica;
Assignee: The United States of America as represented by the Department of Health and Human Services (Washington, DC)
Primary Examiner: Smith; Lynette R. F.
Assistant Examiner: Portner; Ginny Allen
Attorney, Agent or Firm: Needle & Rosenberg, P.C.
The present invention provides a method of treating or preventing inflammation in a subject, comprising administering to the subject an effective amount of cholera toxin subunit B. The present invention also provides a method of decreasing the activity of interferon gamma in a subject, comprising administering to the subject an effective amount of cholera toxin subunit B. Further provided is a method of decreasing the activity of IL-12 in a subject, comprising administering to the subject an effective amount of cholera toxin subunit B. Additionally, the present invention provides a method of treating or preventing a Th1 T-cell mediated autoimmune disorder in a subject, comprising administering to the subject an effective amount of cholera toxin subunit B. |
|
DETAILED DESCRIPTION What is claimed is: 1.
A method of treating inflammatory bowel disease in a subject diagnosed with inflammatory bowel disease, comprising administering to the subject a therapeutically effective amount of cholera toxin subunit B wherein cholera toxin subunit B is not administered with an antigen and wherein administration is mucosal.
2.
The method of claim 1, wherein the subject is a mammal.
3.
The method of claim 2, wherein the mammal is a human.
4.
The method of claim 1, wherein the inflammatory bowel disease is Crohn's disease.
5.
The method of claim 1, wherein the inflammatory bowel disease is ulcerative colitis.
6.
The method of claim 1, wherein the administration is oral or intrarectal.
7.
The method of claim 1, wherein the amount of cholera toxin subunit B administered is between at least about 0.
05 mg/kg body weight and at least about 0.
5 mg/kg body weight.
8.
A method of decreasing the activity of interferon gamma in a subject diagnosed with inflammatory bowel disease, comprising administering to the subject a therapeutically effective amount of cholera toxin subunit B wherein cholera toxin subunit B is not administered with an antigen, and wherein administration is mucosal.
9.
The method of claim 8, wherein the subject is a mammal.
10.
The method of claim 9, wherein the mammal is a human.
11.
The method of claim 8, wherein the inflammatory bowel disease is Crohn's disease.
12.
The method of claim 8, wherein the inflammatory bowel disease is ulcerative colitis.
13.
The method of claim 8, wherein the administration is oral or intrarectal.
14.
The method of claim 8, wherein the amount of cholera toxin subunit B administered is between at least about 0.
05 mg/kg body weight and at least about 0.
5 mg/kg body weight.
15.
A method of decreasing the activity of IL-12 in a subject diagnosed with inflammatory bowel disease, comprising administering to the subject a therapeutically effective amount of cholera toxin subunit B wherein cholera toxin subunit B is not administered with an antigen, and wherein administration is mucosal
|
| Related patents |
|
|
Mammalian haemoglobin compatible with blood plasma, cross-linked and conjugated with polyalkylene oxides as artificial medical oxygen carriers, production and use thereof
1. Hemoglobin derivative compatible with human and non-human animal plasma, comprising hemoglobin crosslinked by means of a crosslinker for proteins and a polyalkylene ...
|
|
|
Anti hepatitis C virus antibody and uses thereof
OF THE PRESENT INVENTION Accordingly, the technical problem of the invention is to provide means and methods for the treatment and prevention of HCV infection in humans....
|
|
|
Chemical and/or biological decontamination system
OF THE INVENTION The present invention provides a composition that is effective in the decontamination of chemical agents and/or biological pathogens. The biological ...
|
|
|
Immunostimulant bacterial membrane fractions in cancer treatment
The invention claimed is: 1. A method of stimulating an immune response and/or inducing an antitumor immune response in a mammal, including a human, in need thereof, ...
|
|
|
Cloning and characterization of a human adenylyl cyclase
One aspect of the invention is an isolated and purified human type VI adenylyl cyclase (hAC6) polypeptide comprising the amino acid sequence of FIG. 1 (SEQ ID NO:2). A...
|
|
|
Tumor antigen based on products of the tumor suppressor gene WT1
What is claimed is: 1. An isolated polypeptide which consists of at most 12 contiguous amino acid residues of a human WT1 protein, wherein the polypeptide comprises SEQ I...
|
|
|
Methods of inhibiting GPR-9-6 function
The invention relates to an antibody (immunoglobulin) or functional fragment thereof (e.g., an antigen-binding fragment) which binds to a mammalian GPR-9-6 (GPR-9-6 is ...
|
|
|
Method for cloning of a rare, specifically mutated cell
The invention is a new and improved method for reliably detecting the presence of a rare cell having a desired nucleotide mutation that was introduced by a sequence-...
|
|
|
Vaccine against Gram-negative bacterial infections
OF THE PREFERRED EMBODIMENTS According to the present invention, a non-covalent, polyvalent complex between purified, detoxified LPS ("DLPS") derived from E. coli and ...
|
|
|
Modified human hemoglobin, blood substitutes containing the same, and vectors for expressing the modified hemoglobin
The present invention relates to modified .beta.-chains of human hemoglobin having an oxygen binding affinity equal to or less than natural human hemoglobin. Preferably, ...
|
|
|
Drugs 
